MEDELLIN, Colombia & TORONTO--(BUSINESS WIRE)--FCM Global S.A.S. (“FCM”), a pioneer within Colombia in the use of cannabinoids and terpenes for medicinal purposes, announced the opening of its new R&D laboratory in Medellin, Colombia. Dedicated to cannabis medicine, the facility will enable FCM to offer Advisory Services designed to help manufacturers of finished medical cannabis goods worldwide to accelerate their product development cycles while lowering total costs of production. FCM Advisory Services include conceptualization of new products and technologies, finalization of new formulas, pre-clinical and clinical trials, and product testing for efficacy, quality, and safety. These advisory services are integrated with FCM’s VerdeCann Platform, which combines proprietary seed and strain genetics, organic cultivation, and advanced extraction techniques to produce a range of high-quality CBD extracts, oils, and isolates.
FCM benefits in its clinical research efforts from its alliance with CIENSA S.A.S. (“CIENSA”), a Medellin-based health services provider and medical clinic with nearly a decade-long track record of successful treatment for over 15,000 patients. Recognized in Colombia as an innovator in fields such as mitochondrial and plant-based medicines, CIENSA has partnered with FCM to provide an evolving range of cannabis-specific patient services and treatments. FCM and CIENSA plan on future multi-clinic expansion and the joint construction of a VerdeCann Center focused on industry-related education, training, and awareness within Colombia.
Dr. Juan Carlos Restrepo, Chief Science Officer of FCM, said: “By enhancing our platform with R&D capabilities and the CIENSA alliance, FCM is now well-positioned to implement clinical studies, in collaboration with our client-partners, to target specific medical conditions and demonstrate the efficacy of new medical cannabis products through research testing in animal models, cellular lines, and human trials. Colombia’s favorable regulatory framework, widespread acceptance, and thriving research community make it an ideal environment for medical cannabis.”
Carlos Velasquez, CEO and co-founder of FCM, adds: “We believe cannabinoids are the medical science market of the future. By extending our service scope to include world-class research and development we hope to add further value in support of our client-partners, whose product innovations have the potential to improve millions of lives and unlock applications for many poorly-treated maladies.”
About FCM Global S.A.S.
FCM Global S.A.S. is a Colombian-founded medical cannabis platform company with headquarters in Medellin, operations in La Ceja, and a distribution office in Toronto, Canada. FCM provides customized CBD extracts, oils, and isolates to pharmaceutical, nutritional, and cosmetic companies in legal markets worldwide. FCM’s Co-Sourced Colombia model enables its clients to benefit from Colombia’s comparative advantages in medical cannabis. FCM is proud to have been Colombia’s first fully-licensed producer and exporter of non-psychoactive (<1% THC) cannabis extracts for medical and research purposes.
For more information, please visit www.fcm-global.com or email info@verdecann.com.
